

August 07, 2018

Aarti Industries Ltd.

Profitability growth guidance revised to +25%, Margins to improve further

Management upticks profitability guidance to upwards of 25%, margins to Improve further going ahead

Management sounded very much confident on strong profitability growth going ahead and have revised the profitability guidance from 15-20% earlier to now upwards of 25%. We believe strong profitability growth will be on the back of (i) Optimum utilization from the nitro-toluene and ethylation business (ii) Strong demand of Phenylene Diamines(PDA) and increasing prices will lead to growth(iii) Approvals from API pharma business to see strong traction going ahead.

Q1FY19 margins almost in-line, revenue & profits grew strongly

The company has reported EBITDA margins of 17.4% in Q1FY19 as compared to 17.5% in Q1FY18. Margins were almost flat because of increasing raw material cost. Raw material cost have increased by 49.9% y-o-y to INR 664.5 crore. This increase in cost is because of higher off take of raw materials owing to new production facilities of nitro-toluene and ethylation. Raw material prices in speciality chemicals have been more or less constant in Q1FY19.

Price increase in key product is a big trigger going ahead

We believe price increase in key chemicals like PDA, nitro-toluene, NCB etc. will be the key growth driver going ahead. These are high margin products and price increase will lead to much higher quantification in terms of profitability growth.

Margins to expand further post expansion

The company has consistently improved EBITDA margins from FY14-17. However, in FY18 company witnessed decline in margins to the tune of 230 bps and stood at 18.4% as compared to 20.7% in FY17. We believe stability of margins is linked to volumes which had consistently recorded growth of 10-15%. The company adopts a cost + margin model where the effective raw material price hike is passed on to end user with one quarter lag. We believe optimum utilization coupled with operating leverage in new business verticals will lead to improvement in margins and likely to be around 21-22% by FY20E and FY21E.

Valuations


Aarti Industries Ltd has consistent track record of performance in terms of volume growth and revenue visibility. We believe the company will be able to grow in higher double digits going ahead on the back of strong execution and proven leadership record. We continue to maintain **"Strong Buy"** on the stock and assign a target price of INR 1543/share, thereby giving an upside of 19.2% from current valuations.

Financial Snapshot

STRONG BUY^{*}

Downside	Current	Price	Upside			
Scenario	Price	Target	Scenario			
	1294	1543 19.2% ▲				
	Stoc	k Details				
Industry		Speci	ality Chemicals			
Sensex		3769	37692			
Nifty		1138	7			
Bloomber	g Code	ARTC):IN			
Eq. Cap. (I	NR. crore.)	40.65	5			
Face Value	e (INR.)	5				
52-w H/L		1378	/772			
Market Ca	p (INR. cror	e.) 1052	0			

Valuation Data							
	FY18	FY19E	FY20E	FY21E			
P/E (x)	30.3	25.1	22.4	16.2			
P/B (x)	6.4	5.3	4.6	3.9			
EV/EBITDA(x)	15.4	14.0	12.6	9.9			



Shareholding Pattern (in %)								
	Jun'18 Mar'18 Jun'17							
Promoters	53.07	51.08	54.26					
FIIs	4.55	4.34	4.56					
DIIs	14.29	14.17	12.47					
Retail	28.09	30.42	28.7					
Total	100.0	100.0	100.0					

(INR Crores)	FY16	FY17	FY18	FY19E	FY20E	FY21E
Net Sales	3006.6	3163.5	3806.2	4554.5	4824.7	6036.2
Growth%		5.2%	20.3%	19.7%	5.9%	25.1%
EBITDA	572.3	653.5	699.3	870.2	983.8	1254.6
Growth%		14.2%	7.0%	24.5%	13.0%	27.5%
РАТ	268.1	327.5	346.3	418.1	466.9	647.8
Growth%		22.9%	5.5%	20.7%	11.7%	38.7%
EPS (INR)	30.8	38.5	41.0	49.5	55.2	76.6
P/E (x)	14.0	19.8	30.3	25.1	22.4	16.2
P/B (x)	3.1	4.6	6.4	5.3	4.6	3.9
EV/EBITDA(x)	11.0	12.0	15.4	14.0	12.6	9.9

Source: NSPL Research

* Read last page for disclaimer & rating rationale

ANALYST

Vaibhav Chowdhry, vaibhav.chowdhry@nalandasecurities.com, +91-22-6281-9649 ASSOCIATE

Aditya Khetan, aditya.khetan@nalandasecurities.com, +91-22-6281-9647

NALANDA SECURITIES PRIVATE LIMITED



Q1FY19 Result Analysis

(INR Millions)	Q1FY19	Q1FY18	Q4FY18	Y-o-Y	Q-o-Q
Revenue	1078	792	1029	36.2%	4.8%
COGS	660	442	607	49.2%	8.6%
Employee Expenses	51	39	51	32.3%	0.6%
Other Expenses	180	173	191	4.1%	-5.9%
Total Expenses	891	653	849	36.3%	4.9%
EBITDA	188	138	180	35.8%	4.2%
Depreciation	38	32	37	19.0%	2.3%
Other Income	3	0	1	-	-
EBIT	154	107	145	43.8%	6.3%
Finance Cost	46	29	36	57.7%	26.6%
РВТ	107	78	108	38.6%	-0.6%
Taxes	18	15	23	25.5%	-22.3%
Net Profit	89	63	85	41.6%	5.4%
EPS in INR	10.98	7.68	10.42	43.0%	5.4%

• The company revenue recorded growth of 36.2% y-o-y & 4.8% q-o-q to INR 1078 crore.

Raw material cost have increased by 49.9% y-o-y to INR 664.5 crore. This increase in cost is because of higher off take of raw
materials owing to new production facilities of nitro-toluene and ethylation. Raw material prices in speciality chemicals have
been more or less constant in Q1FY19.

 EBITDA recorded growth of 35.8% y-o-y & 4.2% q-o-q to INR 188 crore. EBITDA margins stood at 17.4% in Q1FY19 as compared to 17.5% in Q1FY18 and 17.5% in Q4FY18. Margins were almost flat on despite providing for Mark to Market loss of INR 28.95 crore.

• Depreciation grew by 19% y-o-y & 2.3% q-o-q to INR 38 crore. This increase was due to increase in asset base in Q3FY18 owing to start of new production lines of nitro-toluene and ethylation.

• Finance cost reported growth of INR 57.7% y-o-y & 26.6% q-o-q to INR 46 crore. We believe the increase in finance cost might be on the back of increase in debt to fund the capex and working capital requirements.

- Tax rate in Q1FY19 is 17% as compared to 19% in Q1FY18 and 22% in Q4FY18. Since the plants fall in SEZ Dahej, Gujarat the
 facilities are exempted from paying higher tax and also the company is entitled for MAT entitlement which resulted in lower
 tax rate for Q1FY19
- PAT recorded growth of 41.6% y-o-y & 5.4% q-o-q to INR 89 crore. PAT margins stood at 8.3% in Q1FY19 as compared to 8.0% in Q1FY18 and 8.2% in Q4FY18.

Revenue & EBIT breakup

Revenue breakup (INR Crores)	Q1FY19	Q1FY18	Q4FY18	Y-o-Y	Q-o-Q
Speciality chemicals	848	626	787	35.5%	7.8%
Pharmaceuticals	150	106	174	41.1%	-14.1%
НРС	80	60	68	34.9%	18.6%
Total	1078	792	1029	36.2%	4.8%
EBIT breakup (INR Crores)	Q1FY19	Q1FY18	Q4FY18	Y-o-Y	Q-o-Q
Speciality chemicals	149	113	144	31.8%	3.3%
EBIT Margins	17.5%	18.3%	18.0%		
Pharmaceuticals	26	14	30	91.0%	-12.8%
EBIT Margins	17.4%	17.1%	12.8%		
НРС	2	1	-1	-	-
EBIT Margins	2.5%	-1.4%	1.0%		
Total	68.34	127	173	39.1%	2.2%

Source: NSPL Research

The speciality chemicals reported growth of 35.4% y-o-y & 7.8% q-o-q to INR 848 crore in Q1FY19. The pharma business reported growth of 41.1% y-o-y & de-growth of -14.1% q-o-q to INR 150 crore in Q1FY19. The HPC business reported growth of 34.9% y-o-y & 18.6% q-o-q to INR 80 crore in Q1FY19.

EBIT margins in speciality chemicals stood at 17.5% in Q1FY19 and EBIT margins in pharma stood at 17.4% in Q1FY19.


ANALYST Vaibhav Chowdhry, <u>vaibhav.chowdhry@nalandasecurities.com</u> , +91-22-6281-9649 ASSOCIATE Aditya Khetan, <u>aditya.khetan@nalandasecurities.com</u> , +91-22-6281-9647	NALANDA SECURITIES PRIVATE LIMITED 310-311 Hubtown Solaris, NS Phadke Marg, Opp Teli Gali, Andheri East, Mumbai 69 +91-22-6281-9600 research@nalandasecurities.com www.nalandasecurities.com
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




Q1FY19 conference call highlights


- Raw material cost have increased by 49.9% y-o-y to INR 664.5 crore. This increase in cost is because of higher off take of raw materials owing to new production facilities of nitro-toluene and ethylation. Raw material prices in speciality chemicals have been more or less constant in Q1FY19.
- To insulate itself from rupee volatility the company has entered into forward contracts to hedge its export contracts.
- Further impact of revaluation loss on long term borrowing (ECBs) to the extent of INR 7.23 crore as at 30th June, 2018 has been provided. This loss had been provided in the finance costs of the company.
- Volume grew by 12% in Q1FY19. Realization growth was to the tune of 20-25% in Q1FY19.
- EBITDA impacted by INR 28 crore on account of MTM losses.
- Volumes recorded for the quarter are: NCB = 17,000 MT, Nitro-toluene = 3070 MT, Hydrogenation = 1952 TPM, PDA = 550 TPM.
- NCB business operated at 95% utilization in Q1FY19.
- Nitro-toluene business operated at 40% in Q1FY19. Management expects the business to operate at 80-90% by FY20E.
- Benzene prices for the quarter stood at INR 58/kg.
- Management guided that key end user industries like Dyes & pigments are witnessing strong volume growth and will continue going ahead.
- Prices in key products have seen improvement and sustainability in the long term is seen.
- Capex for the quarter is INR 153 crore. Overall capex of INR 600 crore in FY19E as mentioned in our initiating coverage report.
- Management expects the margins to be higher going ahead owing to increase in prices of high margin products.
- The advance of INR 290-300 crore on INR 10,000 crore deal capex is expected to receive from the next quarter.
- The R&D facility is scheduled to start in Q1FY20. Capex on the same will be INR 75 crore.
- Export contribution to china is reducing because of volume shift from China to India.
- Exports have seen decent growth in Q1FY19.
- Management revised their profitability guidance to upwards of 25%. Previous guidance of 15-20%.
- Home & Personal Care(HPC) chemicals have seen strong performance in Q1FY19. This was on the back of improving utilization & prices in the HPC business.
- Pharma business has shown strong growth in Q1FY19. Pharma business recorded topline growth of 41% y-o-y & bottom-line growth of 91% y-o-y.
- Management guided that 13-14 USDMF's have been commercialized in the quarter.
- API intermediates has shown strong traction in Q1FY19. Management expects the traction to continue going ahead.
- Overall utilization of the pharma business is 70-80%. With API intermediates business improving going ahead, overall pharma business utilization to improve going ahead.







Strong financial performance seen in Q1FY19



EPS growth to remain in double digits going ahead




Source: NSPL Research

ANALYST

Vaibhav Chowdhry, <u>vaibhav.chowdhry@nalandasecurities.com</u>, +91-22-6281-9649 ASSOCIATE

Aditya Khetan, aditya.khetan@nalandasecurities.com, +91-22-6281-9647

Return ratios to remain robust going ahead



.

NALANDA SECURITIES PRIVATE LIMITED

Aarti Industries Ltd | Q1FY19 - Result Update | Page 5



Profit and Loss (INR Crores)	FY15	FY16	FY17	FY18	FY19E	FY20E	FY21E
Net Sales	2908.0	3006.6	3163.5	3806.2	4554.5	4824.7	6036.2
Cost of raw materials	1644.3	1603.5	1673.1	2170.0	2568.9	2644.3	2811.7
Purchase of stock in trade	170.6	115.0	107.5.1	117.5	0.0	0.0	0.0
Change of Inventories	17.2	49.3	-31.6	-105.9	0.0	0.0	0.0
Employee Benefit Expenses	93.6	120.7	152.3	190.1	219.6	253.7	293.0
Other Expenses	516.5	545.8	614.4	735.3	895.7	942.9	1011.9
TOTAL EXPENDITURE	2442.3	2434.3	2510.0	3106.9	3684.2	3840.9	4781.6
EBIDTA	465.7	572.3	653.5	699.3	870.2	983.8	1254.6
Other Income	5.5	5.9	2.0	7.8	2.9	3.0	3.0
Depreciation	82.0	98.5	122.5	146.2	170.5	193.8	209.8
EBIT	389.2	479.8	532.9	560.8	702.6	792.9	1047.8
Interest	138.0	117.0	117.3	131.7	173.3	201.9	227.8
Exceptional Items	3.5	0.0	0.0	0.0	0.0	0.0	0.0
PBT	254.8	362.8	415.6	429.2	529.3	591.0	820.0
Tax	61.0	94.6	88.1	82.9	111.1	124.1	172.2
PAT	193.7	268.1	327.5	346.3	418.1	466.9	647.8
Profit attributable to Non Control. Interest	-1.7	-11.2	-11.8	-13.2	-15.9	-17.8	-24.6
Share of Profit/Loss of Associates							
PAT	13.9 205.9	0.0 256.9	0.0 315.8	0.0	0.0 402.2	0.0 449.1	0.0 623.2
EPS in Rs	205.9						76.6
		30.8	38.5	41.0	49.5	55.2	
Dividend Amount	52.0	68.8	67.4	66.1	79.3	105.8	185.1
Balance Sheet (INR Crores)	FY15	FY16	FY17	FY18	FY19E	FY20E	FY21E
Share Capital	44.3	41.7	41.1	40.7	40.7	40.7	40.7
Reserves & Surplus	1025.3	1095.6	1321.4	1537.8	1846.7	2171.4	2576.8
Shareholders Fund	1069.6	1137.3	1362.5	1578.4	1887.3	2212.1	2617.5
Non Controlling Interest	5.9	52.1	63.9	77.0	93.0	103.8	144.1
- Long Term Borrowings	419.1	526.8	596.4	908.3	1018.3	1118.3	1168.3
- Deferred Tax Liabilities(Net)	102.7	127.1	155.4	177.4	231.3	259.1	344.8
- Other Non Current Liabilities	0.2	0.2	0.5	0.0	0.5	0.5	0.5
Total Non Current Liabilities	521.9	654.0	752.3	1085.7	1250.0	1377.8	1513.5
- Short Term Borrowings	648.3	706.4	839.3	1012.5	1162.5	1262.5	1362.5
- Trade Payables	248.8	305.2	299.7	357.5	487.1	454.7	623.7
- Other Current Liabilities	156.6	91.0	153.6	185.3	204.5	217.3	223.7
- Short Term Provisions	14.6	20.5	27.8	31.0	41.7	48.2	55.7
Total Current Liabilities	1068.4	1123.1	1320.4	1586.3	1895.8	1982.7	2265.6
TOTAL EQUITY & LIABILITIES	2665.7	2966.5	3499.1	4327.5	5126.1	5676.4	6540.7
Fixed Assets	966.9	1245.5	1694.9	1996.2	2399.1	2809.0	3206.1
- Capital Work in Progress	193.0	313.0	269.5	436.2	520.9	545.1	439.5
- Goodwill	0.0	0.4	0.4	0.4	0.4	0.4	0.4
- Intangible Assets under development	0.0	0.0	1.7	1.3	1.3	1.3	1.3
- Non Current investments	172.9	41.3	47.0	47.2	49.9	53.2	56.8
- Other Non Current Assets	103.3	132.3	168.4	225.2	269.5	337.7	385.2
Total Non Current Assets	1436.1	1732.5	2181.9	2706.5	3241.1	3746.8	4089.3
- Other Current Financial Assets	172.9	167.9	168.7	224.8	296.0	337.7	385.2
- Inventories	551.7	495.2	571.4	747.3	801.1	792.7	824.9
- Trade Recievables	439.0	523.4	524.7	590.8	657.1	664.8	989.0
- Cash	33.7	29.0	28.5	32.1	89.8	86.2	200.9
- Other Current Assets	32.3	18.5	23.9	26.0	41.0	48.2	51.4
Total Current Assets	1229.7	1234.0	1317.2	1620.9	1885.0	1929.7	2451.4
TOTAL ASSETS	2665.7	2966.4	3499.0	4327.4	5126.1	5676.4	6540.7

Source: NSPL Research

ANALYST Vaibhav Chowdhry, <u>vaibhav.chowdhry@nalandasecurities.com</u>, +91-22-6281-9649 ASSOCIATE Aditya Khetan, <u>aditya.khetan@nalandasecurities.com</u>, +91-22-6281-9647

NALANDA SECURITIES PRIVATE LIMITED

Aarti Industries Ltd | Q1FY19 - Result Update | Page 6



Cash Flow (INR Crores)	FY15	FY16	FY17	FY18	FY19E	FY20E	FY218
Cash Flow from Operating Activities							
Profit before tax	251.3	362.8	415.6	429.2	529.3	591.0	820.0
Op. Profit before Working Capital Change	466.6	575.0	654.4	707.0	873.1	986.8	1257.
Op. Profit After Working Capital Changes	397.7	671.5	567.5	442.8	782.0	857.1	986.0
Taxes Paid(Net)	-58.3	-97.8	-97.5	-82.9	-111.1	-124.1	-172.
Net Cash Flow from Operating Activities	339.5	573.6	470.1	359.9	670.9	733.0	813.9
ash Flow from Investing Activities							
Purchased of Fixed Assets	-303.1	-466.5	-530.2	-576.3	-603.8	-607.0	-400.
Sale/(Purchase) of Investments	-4.2	-4.0	0.8	-0.3	-2.7	-3.3	-3.6
Net Cash Flow from Investing Activities	-297.7	-452.0	-528.9	-576.5	-606.5	-610.3	-403.
Cash Flow from Financing Activities							
Proceeds From Long-Term Borrowings	285.0	201.1	200.0	311.8	110.0	100.0	50.0
Proceeds/Repayment from Other Borrow	-38.5	52.7	132.9	173.2	150.0	100.0	100.0
Interest Paid	-138.0	-117.0	-117.3	-131.7	-173.3	-201.9	-227.
Dividend Paid	-48.3	-95.2	-0.6	-77.8	-93.3	-124.4	-217.
Net Cash Flow from Financing Activities	-23.0	-128.4	58.3	220.2	-6.7	-126.3	-295.
Net Inc/(Dec) in Cash and Cash Equivalent	18.9	-6.8	-0.5	3.6	57.7	-3.7	114.7
Cash and Cash Equivalents at Beginning	14.9	33.7	29.0	28.5	32.1	89.8	86.2
otal Cash & Cash Equivalent	33.7	29.0	28.5	32.1	89.8	86.2	200.9
inancial Ratios	FY15	EV16	EV17	FY18	EV10E	FY20E	FY21
inancial Ratios		FY16	FY17		FY19E	FTZUE	
Revenue Growth	10.5%	3.4%	5.2%	20.3%	19.7%	5.9%	25.1%
EBITDA Growth	16.0%	22.9%	14.2%	7.0%	24.5%	13.0%	27.5%
PAT Growth							38.7%
	26.7%	24.8%	22.9%	5.5%	20.7%	11.7%	
PBT Growth	23.6%	42.4%	14.6%	3.3%	23.3%	11.7%	38.79
Raw Materials Growth	8.8%	-3.5%	-1.4%	25.1%	17.8%	2.9%	6.3%
Aargin Profile							
EBITDA Margins	16.0%	19.0%	20.7%	18.4%	19.1%	20.4%	20.8%
PBT Margins	8.8%	12.1%	13.1%	11.3%	11.6%	12.2%	13.6%
PAT Margins	7.1%	8.5%	10.0%	8.8%	8.8%	9.3%	10.39
Gross Margins	63.0%	58.8%	55.1%	57.3%	56.4%	54.8%	46.6%
5							
eturn Ratios							
ROCE	17.1%	19.8%	18.2%	15.7%	16.7%	16.7%	19.8%
ROIC	15.6%	17.4%	17.6%	15.8%	16.4%	16.4%	18.79
ROA	7.3%	7.9%	8.1%	7.0%	7.4%	7.4%	9.5%
Operating ROA	16.5%	17.7%	16.7%	14.8%	16.1%	16.1%	19.2%
ebt Ratios							
Debt to Equity	1.0	1.1	1.1	1.3	1.2	1.1	1.0
Debt to Assets	0.5	0.4	0.4	0.4	0.5	0.4	0.4
Debt to Total Capital	0.5	0.5	0.5	0.6	0.6	0.5	0.5
Interest Coverage	2.8	4.1	4.5	4.3	4.1	3.9	4.6
PAT Margin	7 10/	0 E0/	10.0%	0 00/	0 00/	0.20/	10.20
PAT Margin	7.1%	8.5%	10.0%	8.8%	8.8%	9.3%	10.39
Asset Turnover	1.1	1.1	1.0	1.0	1.0	0.9	1.0
Equity Multiplier	2.5	2.6	2.6	2.7	2.7	2.6	2.5
ROE	19.2%	23.3%	25.3%	22.7%	23.2%	21.9%	25.8%
Source: NSPL Research							

Aarti Industries Ltd | Q1FY19 - Result Update | Page 7



	Ra	ting Legend			
Date	CMP (INR)	Target Price (INR)	Recommendation	Strong Buy	More than 15%
July 16, 2018 – IC	1240	1543	Strong Buy	Buy	5% - 15%
August 07, 2018	1294	1543	Strong Buy	Hold	0 – 5%
				Reduce	-5% - 0
				Sell	Less than -5%

Disclaimer:

This report has been prepared by Nalanda Securities Pvt. Ltd("NSPL") and published in accordance with the provisions of Regulation 18 of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, for use by the recipient as information only and is not for circulation or public distribution. NSPL includes subsidiaries, group and associate companies, promoters, directors, employees and affiliates. This report is not to be altered, transmitted, reproduced, copied, redistributed, uploaded, published or available to others, in any form, in whole or in part, for any purpose without prior written permission from NSPL. The projections and the forecasts described in this report are based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections are forecasts described in this report are used upon a diviations will likely increase over the period of time. All the projections and forecasts described in this report independently. None of the forecasts were prepared with a view towards compliance with published guidelines or generally accepted accounting principles.

This report should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this report nor anything contained therein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. It does not constitute a personal recommendation or take into account the particular investment objective, financial situation or needs of individual clients. The research analysts of NSPL have adhered to the code of conduct under Regulation 24 (2) of the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. The recipients of this report must make their own investment decisions, based on their own investment objectives, financial situation or needs and other factors. The recipients should consider and independently evaluate whether it is suitable for its/ his/ her/their particular circumstances and if necessary, seek professional / financial advice as there is substantial risk of loss. NSPL does not take any responsibility thereof. Any such recipient shall be responsible for conducting his/her/its/their own investigation and analysis of the information contained or referred to in this report and income from them may go up as well as down, and investors may realize profit/loss on their investments. Past performance is not a guide for future performance. Actual results may differ materially from those set forth in the projection.

Except for the historical information contained herein, statements in this report, which contain words such as 'will', 'would', etc., and similar expressions or variations of such words may constitute 'forward-looking statements'. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. Forward-looking statements are not predictions and may be subject to change without notice. NSPL undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date thereof. NSPL accepts no liabilities for any loss or damage of any kind arising out of use of this report.

This report has been prepared by NSPL based upon the information available in the public domain and other public sources believed to be reliable. Though utmost care has been taken to ensure its accuracy and completeness, no representation or warranty, express or implied is made by NSPL that such information is accurate or complete and/or is independently verified. The contents of this report represent the assumptions and projections of NSPL and NSPL does not guarantee the accuracy or reliability of any projection, assurances or advice made herein. Nothing in this report constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or appropriate to recipients' specific circumstances. This report is based / focused on fundamentals of the Company and forward-looking statements as such, may not match with a report on a company's technical analysis report. This report may not be followed by any specific event update/ follow-up.

Following table contains the disclosure of interest in order to adhere to utmost transparency in the matter;

Disclosure of Interest Statement				
Details of Nalanda Securities Pvt. Limited (NSPL)		NSPL is a Stock Broker registered with BSE, NSE and MCX - SX in all the major segments viz. Cash, F & O and CDS segments. Further, NSPL is a Registered Portfolio Manager and is registered with SEBI SEBI Registration Number: INH000004617		
Details of Disciplinary History of NSPL	No	disciplinary action is / was running / initiated against NSPL		
Research analyst or NSPL or its relatives'/associates' financial interest in	No	(except to the extent of shares held by Research analyst or NSPL or its		
the subject company and nature of such financial interest	rela	atives'/associates')		
Whether Research analyst or NSPL or its relatives'/associates' is holding	NO			
the securities of the subject company				
Research analyst or NSPL or its relatives'/associates' actual/beneficial				
ownership of 1% or more in securities of the subject company, at the	NO			
end of the month immediately preceding the date of publication of the				
document				
Research analyst or NSPL or its relatives'/associates' any other material	NO			
conflict of interest at the time of publication of the document		,		
research analyst or NSPL or its associates received any compensation		NO		
from the subject company in the past 12 months				
Has research analyst or NSPL or its associates managed or co-managed				
public offering of securities for the subject company in the past 12 month				
Has research analyst or NSPL or its associates received any compensation				
for investment banking or merchant banking or brokerage services from	NO			
the subject company in the past 12 months				
Has research analyst or NSPL or its associates received any compensation				
for products or services other than investment banking or merchant	NO			
banking or brokerage services from the subject company in the past 12	NO			
months				
Has research analyst or NSPL or its associates received any compensation				
or other benefits from the subject company or third party in connection	NO			
with the document.				
Has research analyst served as an officer, director or employee of the	NO			
subject company				
Has research analyst or NSPL engaged in market making activity for the	NO			
subject company				
Other disclosures	NO			
ANALYST		NALANDA SECURITIES PRIVATE LIMITED		
Vaibhav Chowdhry, <u>vaibhav.chowdhry@nalandasecurities.com</u> , +91-22-6281-9649		310-311 Hubtown Solaris, NS Phadke Marg, Opp Teli Gali, Andheri East, Mumbai 69		
ASSOCIATE		+91-22-6281-9600 research@nalandasecurities.com www.nalandasecurities.com		
Aditya Khetan, aditya.khetan@nalandasecurities.com, +91-22-6281-9647				